Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Barclays analyst Sven Merkt maintained a Sell rating on Sage Group plc (SGE – Research Report) today and set a price target of £10.80. The ...

Jefferies increased its price target on Sage shares from GBP15.00 to GBP16.00, reaffirming its Buy rating on the company. The revised price target comes after Sage's first quarter 2025 report, which ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

The Tyneside-based FTSE100 firm issued first quarter trading results for the three months to the end of December which showed ...

In a report released today, Charles Brennan from Jefferies maintained a Buy rating on Sage Group plc (SGE – Research Report), with a price ...

Britain's Sage Group on Thursday maintained its annual revenue forecasts after the software firm posted a 10% rise in underlying revenue for the first quarter, buoyed by higher demand, especially in ...

Business Insider's personal finance team compared Sage Mortgage to the best mortgage lenders and found it to be a standard lender Sage Mortgage has loan options that should meet most borrowers ...

AUSTIN, Texas--(BUSINESS WIRE)--Blue Sage Capital, a leading lower-middle market private equity firm, today announced the final close of Blue Sage Capital IV, L.P. (the “Fund”), at $618 ...